We reported a rare case of 47-year-old female was diagnosed with lung adenocarcinoma and treated with three cycles of chemotherapy. A biopsy acquired after disease progression revealed concurrent KRAS mutation and ALK translocation by a NGS assay. Based on molecular findings, treatment was initiated with crizotinib in September, 2016. After 2 months of therapy, the patient achieved a partial response. Afterwards, the patient was further administrated with crizotinib for 9 months with a stable disease before tumor progression.A further understanding of the molecular biology with multiple oncogenic drivers will promote the optimal treatment for NSCLC. READ ARTICLE
Journal of Thoracic Oncology DOI:10.1016/j.jtho.2019.08.2332
Authors: Y. Zhu, W. Wang, C. Xu, X. Li, W. Zhuang, K. Du, G. Chen, M. Fang, T. Lv, Y. Song
